Health
CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A – News-Medical.Net
Researchers at Children’s Hospital of Philadelphia have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia…
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies,…
-
Noosa News19 hours agoTwo trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business20 hours agoUp 105% in a year, are Pro Medicus shares still a good buy today?
-
Noosa News16 hours agoQueensland man sentenced to four years imprisonment after string of terror offences
-
Business18 hours agoEverything you need to know about the Coles dividend